In this edition of Biotech Banter, Motley Fool contributor Brian Orelli and health care bureau chief Max Macaluso discuss an FDA delay for MannKind's Afrezza, clinical trial results from Amgen's T-VEC, up-and-coming biotech Agios, and the biotech "Tweet of the Week."
The latest from The Motley Fool's biotech show "Biotech Banter."
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo